Literature DB >> 30084834

Consensus on Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.

Gregory M Chen1, Lavanya Kannan2,3, Ludwig Geistlinger2,3, Victor Kofia1,4,5, Zhaleh Safikhani1,4,5, Deena M A Gendoo1,4, Giovanni Parmigiani6, Michael Birrer7, Benjamin Haibe-Kains8,4,5,9, Levi Waldron10,3.   

Abstract

Purpose: The majority of ovarian carcinomas are of high-grade serous histology, which is associated with poor prognosis. Surgery and chemotherapy are the mainstay of treatment, and molecular characterization is necessary to lead the way to targeted therapeutic options. To this end, various computational methods for gene expression-based subtyping of high-grade serous ovarian carcinoma (HGSOC) have been proposed, but their overlap and robustness remain unknown.Experimental Design: We assess three major subtype classifiers by meta-analysis of publicly available expression data, and assess statistical criteria of subtype robustness and classifier concordance. We develop a consensus classifier that represents the subtype classifications of tumors based on the consensus of multiple methods, and outputs a confidence score. Using our compendium of expression data, we examine the possibility that a subset of tumors is unclassifiable based on currently proposed subtypes.
Results: HGSOC subtyping classifiers exhibit moderate pairwise concordance across our data compendium (58.9%-70.9%; P < 10-5) and are associated with overall survival in a meta-analysis across datasets (P < 10-5). Current subtypes do not meet statistical criteria for robustness to reclustering across multiple datasets (prediction strength < 0.6). A new subtype classifier is trained on concordantly classified samples to yield a consensus classification of patient tumors that correlates with patient age, survival, tumor purity, and lymphocyte infiltration.Conclusions: A new consensus ovarian subtype classifier represents the consensus of methods and demonstrates the importance of classification approaches for cancer that do not require all tumors to be assigned to a distinct subtype. Clin Cancer Res; 24(20); 5037-47. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30084834      PMCID: PMC6207081          DOI: 10.1158/1078-0432.CCR-18-0784

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  38 in total

1.  survcomp: an R/Bioconductor package for performance assessment and comparison of survival models.

Authors:  Markus S Schröder; Aedín C Culhane; John Quackenbush; Benjamin Haibe-Kains
Journal:  Bioinformatics       Date:  2011-09-07       Impact factor: 6.937

2.  Molecular subtypes of high-grade serous ovarian cancer: the holy grail?

Authors:  Levi Waldron; Markus Riester; Michael Birrer
Journal:  J Natl Cancer Inst       Date:  2014-09-30       Impact factor: 13.506

3.  Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.

Authors:  Gottfried E Konecny; Chen Wang; Habib Hamidi; Boris Winterhoff; Kimberly R Kalli; Judy Dering; Charles Ginther; Hsiao-Wang Chen; Sean Dowdy; William Cliby; Bobbie Gostout; Karl C Podratz; Gary Keeney; He-Jing Wang; Lynn C Hartmann; Dennis J Slamon; Ellen L Goode
Journal:  J Natl Cancer Inst       Date:  2014-09-30       Impact factor: 13.506

4.  Identification of homogeneous and heterogeneous variables in pooled cohort studies.

Authors:  Xin Cheng; Wenbin Lu; Mengling Liu
Journal:  Biometrics       Date:  2015-03-02       Impact factor: 2.571

5.  A prognostic gene expression index in ovarian cancer - validation across different independent data sets.

Authors:  Carsten Denkert; Jan Budczies; Silvia Darb-Esfahani; Balazs Györffy; Jalid Sehouli; Dominique Könsgen; Robert Zeillinger; Wilko Weichert; Aurelia Noske; Ann-Christin Buckendahl; Berit M Müller; Manfred Dietel; Hermann Lage
Journal:  J Pathol       Date:  2009-06       Impact factor: 7.996

6.  Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.

Authors:  Roel G W Verhaak; Pablo Tamayo; Ji-Yeon Yang; Diana Hubbard; Hailei Zhang; Chad J Creighton; Sian Fereday; Michael Lawrence; Scott L Carter; Craig H Mermel; Aleksandar D Kostic; Dariush Etemadmoghadam; Gordon Saksena; Kristian Cibulskis; Sekhar Duraisamy; Keren Levanon; Carrie Sougnez; Aviad Tsherniak; Sebastian Gomez; Robert Onofrio; Stacey Gabriel; Lynda Chin; Nianxiang Zhang; Paul T Spellman; Yiqun Zhang; Rehan Akbani; Katherine A Hoadley; Ari Kahn; Martin Köbel; David Huntsman; Robert A Soslow; Anna Defazio; Michael J Birrer; Joe W Gray; John N Weinstein; David D Bowtell; Ronny Drapkin; Jill P Mesirov; Gad Getz; Douglas A Levine; Matthew Meyerson
Journal:  J Clin Invest       Date:  2012-12-21       Impact factor: 14.808

7.  POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.

Authors:  Beth Y Karlan; Judy Dering; Christine Walsh; Sandra Orsulic; Jenny Lester; Lee A Anderson; Charles L Ginther; Marlena Fejzo; Dennis Slamon
Journal:  Gynecol Oncol       Date:  2013-12-22       Impact factor: 5.482

8.  Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer.

Authors:  Andrew McPherson; Andrew Roth; Emma Laks; Tehmina Masud; Ali Bashashati; Allen W Zhang; Gavin Ha; Justina Biele; Damian Yap; Adrian Wan; Leah M Prentice; Jaswinder Khattra; Maia A Smith; Cydney B Nielsen; Sarah C Mullaly; Steve Kalloger; Anthony Karnezis; Karey Shumansky; Celia Siu; Jamie Rosner; Hector Li Chan; Julie Ho; Nataliya Melnyk; Janine Senz; Winnie Yang; Richard Moore; Andrew J Mungall; Marco A Marra; Alexandre Bouchard-Côté; C Blake Gilks; David G Huntsman; Jessica N McAlpine; Samuel Aparicio; Sohrab P Shah
Journal:  Nat Genet       Date:  2016-05-16       Impact factor: 38.330

9.  Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.

Authors:  Åslaug Helland; Michael S Anglesio; Joshy George; Prue A Cowin; Cameron N Johnstone; Colin M House; Karen E Sheppard; Dariush Etemadmoghadam; Nataliya Melnyk; Anil K Rustgi; Wayne A Phillips; Hilde Johnsen; Ruth Holm; Gunnar B Kristensen; Michael J Birrer; Richard B Pearson; Anne-Lise Børresen-Dale; David G Huntsman; Anna deFazio; Chad J Creighton; Gordon K Smyth; David D L Bowtell
Journal:  PLoS One       Date:  2011-04-13       Impact factor: 3.240

10.  CoINcIDE: A framework for discovery of patient subtypes across multiple datasets.

Authors:  Catherine R Planey; Olivier Gevaert
Journal:  Genome Med       Date:  2016-03-09       Impact factor: 11.117

View more
  26 in total

Review 1.  Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation.

Authors:  Lana E Kandalaft; Denarda Dangaj Laniti; George Coukos
Journal:  Nat Rev Cancer       Date:  2022-09-15       Impact factor: 69.800

Review 2.  Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.

Authors:  Anne M Macpherson; Simon C Barry; Carmela Ricciardelli; Martin K Oehler
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

3.  Multisite Tumor Sampling Reveals Extensive Heterogeneity of Tumor and Host Immune Response in Ovarian Cancer.

Authors:  Sotirios Lakis; Vassiliki Kotoula; Georgia-Angeliki Koliou; Ioannis Efstratiou; Sofia Chrisafi; Alexios Papanikolaou; Pantelis Zebekakis; George Fountzilas
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

4.  The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer.

Authors:  Matthew Schwede; Levi Waldron; Samuel C Mok; Wei Wei; Azfar Basunia; Melissa A Merritt; Constantine S Mitsiades; Giovanni Parmigiani; David P Harrington; John Quackenbush; Michael J Birrer; Aedín C Culhane
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-12-23       Impact factor: 4.254

5.  Phenotypic and Functional Analyses of B7S1 in Ovarian Cancer.

Authors:  Dongli Cai; Fang Wang; Changgang Wang; Liping Jin
Journal:  Front Mol Biosci       Date:  2021-07-09

6.  Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).

Authors:  Aline Talhouk; Joshy George; Chen Wang; Ellen L Goode; Susan J Ramus; Jennifer A Doherty; David D Bowtell; Michael S Anglesio; Timothy Budden; Tuan Zea Tan; Derek S Chiu; Stefan Kommoss; Huei San Leong; Stephanie Chen; Maria P Intermaggio; Blake Gilks; Tayyebeh M Nazeran; Mila Volchek; Wafaa Elatre; Rex C Bentley; Janine Senz; Amy Lum; Veronica Chow; Hanwei Sudderuddin; Robertson Mackenzie; Samuel C Y Leong; Geyi Liu; Dustin Johnson; Billy Chen; Aocs Group; Jennifer Alsop; Susana N Banerjee; Sabine Behrens; Clara Bodelon; Alison H Brand; Louise Brinton; Michael E Carney; Yoke-Eng Chiew; Kara L Cushing-Haugen; Cezary Cybulski; Darren Ennis; Sian Fereday; Renée T Fortner; Jesús García-Donas; Aleksandra Gentry-Maharaj; Rosalind Glasspool; Teodora Goranova; Casey S Greene; Paul Haluska; Holly R Harris; Joy Hendley; Brenda Y Hernandez; Esther Herpel; Mercedes Jimenez-Linan; Chloe Karpinskyj; Scott H Kaufmann; Gary L Keeney; Catherine J Kennedy; Martin Köbel; Jennifer M Koziak; Melissa C Larson; Jenny Lester; Liz-Anne Lewsley; Jolanta Lissowska; Jan Lubiński; Hugh Luk; Geoff Macintyre; Sven Mahner; Iain A McNeish; Janusz Menkiszak; Nikilyn Nevins; Ana Osorio; Oleg Oszurek; José Palacios; Samantha Hinsley; Celeste L Pearce; Malcolm C Pike; Anna M Piskorz; Isabelle Ray-Coquard; Valerie Rhenius; Cristina Rodriguez-Antona; Raghwa Sharma; Mark E Sherman; Dilrini De Silva; Naveena Singh; Peter Sinn; Dennis Slamon; Honglin Song; Helen Steed; Euan A Stronach; Pamela J Thompson; Aleksandra Tołoczko; Britton Trabert; Nadia Traficante; Chiu-Chen Tseng; Martin Widschwendter; Lynne R Wilkens; Stacey J Winham; Boris Winterhoff; Alicia Beeghly-Fadiel; Javier Benitez; Andrew Berchuck; James D Brenton; Robert Brown; Jenny Chang-Claude; Georgia Chenevix-Trench; Anna deFazio; Peter A Fasching; María J García; Simon A Gayther; Marc T Goodman; Jacek Gronwald; Michelle J Henderson; Beth Y Karlan; Linda E Kelemen; Usha Menon; Sandra Orsulic; Paul D P Pharoah; Nicolas Wentzensen; Anna H Wu; Joellen M Schildkraut; Mary Anne Rossing; Gottfried E Konecny; David G Huntsman; Ruby Yun-Ju Huang
Journal:  Clin Cancer Res       Date:  2020-06-17       Impact factor: 13.801

7.  A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis.

Authors:  Laudine Communal; Noemi Roy; Maxime Cahuzac; Kurosh Rahimi; Martin Köbel; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

8.  Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma.

Authors:  Ludwig Geistlinger; Sehyun Oh; Marcel Ramos; Lucas Schiffer; Rebecca S LaRue; Christine M Henzler; Sarah A Munro; Claire Daughters; Andrew C Nelson; Boris J Winterhoff; Zenas Chang; Shobhana Talukdar; Mihir Shetty; Sally A Mullany; Martin Morgan; Giovanni Parmigiani; Michael J Birrer; Li-Xuan Qin; Markus Riester; Timothy K Starr; Levi Waldron
Journal:  Cancer Res       Date:  2020-08-03       Impact factor: 12.701

9.  Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens.

Authors:  Allison L Hunt; Nicholas W Bateman; Waleed Barakat; Sasha Makohon-Moore; Brian L Hood; Kelly A Conrads; Ming Zhou; Valerie Calvert; Mariaelena Pierobon; Jeremy Loffredo; Tracy J Litzi; Julie Oliver; Dave Mitchell; Glenn Gist; Christine Rojas; Brian Blanton; Emma L Robinson; Kunle Odunsi; Anil K Sood; Yovanni Casablanca; Kathleen M Darcy; Craig D Shriver; Emanuel F Petricoin; Uma N M Rao; G Larry Maxwell; Thomas P Conrads
Journal:  iScience       Date:  2021-06-21

10.  High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification.

Authors:  Siel Olbrecht; Pieter Busschaert; Junbin Qian; Adriaan Vanderstichele; Liselore Loverix; Toon Van Gorp; Els Van Nieuwenhuysen; Sileny Han; Annick Van den Broeck; An Coosemans; Anne-Sophie Van Rompuy; Diether Lambrechts; Ignace Vergote
Journal:  Genome Med       Date:  2021-07-09       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.